RS Research, a Teknopark Istanbul, Turkey-based nanomedicine startup, raised €1.1m in funding.
Technology focused venture capital fund ACT Venture Partners, whose main backer is the European Investment Fund (EIF), provided the funds.
The company intends to use the funds to continue to develop its drug delivery platform from preclinical steps towards investigational new drug applications.
Founded by Dr. Rana Sanyal (Chief Science Officer) and Sena Nomak (Chief Operating Officer) in March 2015, RS Research is a therapeutics company developing novel nanomedicines which are in various stages of preclinical development for treatment of cancer. Along with advancing their own candidates toward clinic, the company provides preclinical services to industrial and academic partners bringing to them specific expertise in biosimilar characterization as well as in vivo experiment design.